A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

Inclusion Criteria: * Has a body mass index 18.5 to 32.0 kg/m2, inclusive. * Negative for current SARS-CoV-2 infection by rapid antigen test on Day -1. * Is seropositive to N and/or S SARS-CoV-2 antigens at Screening. * For participants assigned female sex at birth: Is not of childbearing potential OR is of childbearing potential and practicing highly effective contraception. * Is able and willing to provide written informed consent. * NOTE: Other protocol defined inclusion/exclusion criteria apply Exclusion Criteria: * Intends to receive a COVID-19 vaccine/booster within 3 months of Day 1. * Is pregnant, breastfeeding, or seeking pregnancy while on study. * Has a history of a malignancy (or active malignancy), except for participants with basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix who have been treated and cured. * Has had any symptoms of acute respiratory illness (e.g., cough, shortness of breath, sore throat, fatigue, loss of smell, fever), or other febrile illness within 2 weeks prior to dosing. * Has evidence of active infection with HIV, HBV, or HCV. * Has donated more than 500 mL of blood within 60 days before the scheduled dose of study drug. * Had major surgery within 30 days prior to study drug dosing or planned surgeries within 12 months after planned study drug dosing. * Received any investigational drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to Screening or planned administration of any investigational drug or biologic during the study period. * Received immunoglobulin or blood products within 6 months prior to Screening. * Previously received a mAb within 6 months or 5 half-lives (whichever is longer) prior to Screening. * NOTE: Other protocol defined inclusion/exclusion criteria apply